Intravenous Immunoglobulin Market: Industry Size and Growth Trends [2029] Analyzed by TechSci Research

Industry Key Highlights

According to TechSci Research's report, “Intravenous Immunoglobulin Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F,” the Global Intravenous Immunoglobulin Market stood at USD 11.76 billion in 2023 and is projected to grow with a CAGR of 7.01% in the forecast period through 2029. This growth is driven by several factors, including the global demographic shift toward an aging population, advancements in biotechnology and manufacturing processes, and expanding applications of IVIG therapy in treating autoimmune and neurological disorders.

Drivers and Emerging Trends

What Is Fueling the Demand for IVIG Products?

The global demographic shift toward an aging population is a significant driver fueling the demand for IVIG products. Elderly individuals are more susceptible to immunodeficiency disorders, autoimmune diseases, and neurological conditions due to age-related changes in immune function and an increased incidence of chronic illnesses. As the elderly population continues to grow, the prevalence of these conditions is expected to rise, driving the need for IVIG therapy. Moreover, advancements in healthcare infrastructure and access to medical services in emerging economies are improving diagnosis rates and treatment outcomes for elderly patients, further driving market growth.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Intravenous Immunoglobulin Market”

How Are Technological Advancements Boosting the Market?

Advancements in biotechnology and manufacturing processes have played a pivotal role in driving the growth of the IVIG market. Innovations in plasma fractionation technologies have enabled the production of high-quality IVIG products with improved safety and efficacy profiles. Manufacturers are investing in research and development initiatives to enhance the purification and viral inactivation processes, ensuring the elimination of infectious agents and contaminants from IVIG preparations. Improvements in formulation techniques have led to the development of stabilized liquid IVIG formulations that offer convenience in storage and administration, further boosting market adoption. These technological advancements are driving efficiency gains in IVIG production, facilitating scalability, and meeting the growing demand for IVIG therapies worldwide.

Expanding Applications in Treating Autoimmune and Neurological Disorders

Beyond immunodeficiency disorders, IVIG therapy is finding expanding applications in the treatment of autoimmune and neurological disorders. Autoimmune diseases such as immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome (GBS), and myasthenia gravis (MG) are among the conditions benefiting from IVIG treatment. The ability of IVIG to modulate the immune response and mitigate autoimmune reactions has led to its widespread use in managing these conditions. Similarly, in neurological disorders like chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), IVIG has demonstrated efficacy in improving neuromuscular function and reducing disease progression.

Top 10 Companies in the Intravenous Immunoglobulin Market

1. Bio Products Laboratory Ltd.
2. Biotest AG
3. China Biologic Products Holdings Inc.
4. CSL Behring
5. Grifols SA
6. Kedrion SpA
7. Shanghai RAAS Blood Products Co. Ltd
8. Octapharma AG
9. Takeda Pharmaceutical Company Limited
10. Baxter International Inc.

These companies are at the forefront of innovation in the IVIG market, driving growth through strategic initiatives such as mergers and acquisitions, partnerships, and product development.

Competitive Analysis

Strategic Mergers and Acquisitions

Major players in the IVIG market are engaging in strategic mergers and acquisitions to enhance their market presence and expand their product portfolios. For instance, in May 2021, GC Pharma reported that the United States Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for "GC5107 (Immune Globulin Intravenous (Human), 10% Liquid)" intended for the treatment of Primary Humoral Immunodeficiency, a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system.

Download Free Sample Report

Customers can also request for 10% free customization on this report

Collaborations and Partnerships

Collaborations and partnerships are also playing a significant role in market expansion. In April 2023, Takeda entered into an agreement with Canadian Blood Services to deliver innovative therapies to patients with primary and secondary immunodeficiency. Such collaborations enable companies to leverage each other's strengths and resources, leading to the development of advanced IVIG products and expanding their market reach.

Recent Developments Shaping the Market Landscape

Innovative Diagnostic Solutions

In January 2022, Argenx SE, a global immunology company, revealed that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVGART (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have a sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). Such innovations in diagnostic solutions are driving market growth by offering more efficient, accurate, and comprehensive treatment options.

Strategic Collaborations

In March 2022, Sanofi and Seagen Inc. entered into an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology, driving advancements in cancer treatment.

Future Outlook

The future of the IVIG market looks promising, with several factors expected to drive continued growth. The increasing prevalence of diseases such as cancer and osteoporosis, alongside a growing elderly population, is anticipated to sustain market expansion. Additionally, favorable government initiatives and investments in healthcare infrastructure are expected to create new growth opportunities.

What Are the Key Growth Opportunities?

Emerging markets, particularly in the Asia-Pacific region, are poised for substantial growth. Factors such as increasing healthcare expenditure, rising awareness about advanced diagnostic technologies, and significant investments in research and development are contributing to the market's expansion in this region.

10 Benefits of the Research Report

1. Comprehensive Market Analysis: Provides an in-depth analysis of the global IVIG market, covering key trends, drivers, and challenges.
2. Strategic Insights: Offers strategic insights into market opportunities and threats to help businesses make informed decisions.
3. Market Forecasts: Includes market forecasts for 2025-2029, helping businesses plan their strategies effectively.
4. Competitive Landscape: Analyzes the competitive landscape, highlighting key players and their strategies.
5. Regional Insights: Provides detailed insights into regional markets, helping businesses identify growth opportunities in different regions.
6. Technological Advancements: Covers the latest technological advancements in the IVIG industry.
7. End-User Analysis: Analyzes the market based on end-users, helping businesses understand the demand dynamics.
8. Regulatory Landscape: Provides insights into the regulatory landscape and its impact on the market.
9. Investment Opportunities: Identifies potential investment opportunities in the IVIG market.
10. Market Drivers and Restraints: Analyzes the key market drivers and restraints, helping businesses understand the market dynamics.

Emerging Trends and Market Drivers

What Are the Emerging Trends in the IVIG Market?

The global IVIG market is witnessing several emerging trends that are shaping its growth trajectory. One notable trend is the increasing use of IVIG therapy in treating autoimmune and neurological disorders. The ability of IVIG to modulate the immune response and mitigate autoimmune reactions has led to its widespread use in managing conditions such as Guillain-Barré syndrome, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. Additionally, advancements in biotechnology and manufacturing processes are driving efficiency gains in IVIG production, facilitating scalability, and meeting the growing demand for IVIG therapies worldwide.

How Are Advancements in Biotechnology Enhancing IVIG Production?

Advancements in biotechnology and manufacturing processes have played a pivotal role in driving the growth of the IVIG market. Innovations in plasma fractionation technologies have enabled the production of high-quality IVIG products with improved safety and efficacy profiles. Manufacturers are investing in research and development initiatives to enhance the purification and viral inactivation processes, ensuring the elimination of infectious agents and contaminants from IVIG preparations. Improvements in formulation techniques have led to the development of stabilized liquid IVIG formulations that offer convenience in storage and administration, further boosting market adoption.

How Is the Growing Elderly Population Influencing the Market?

The global demographic shift toward an aging population is a significant driver fueling the demand for IVIG products. Elderly individuals are more susceptible to immunodeficiency disorders, autoimmune diseases, and neurological conditions due to age-related changes in immune function and an increased incidence of chronic illnesses. As the elderly population continues to grow, the prevalence of these conditions is expected to rise, driving the need for IVIG therapy. Moreover, advancements in healthcare infrastructure and access to medical services in emerging economies are improving diagnosis rates and treatment outcomes for elderly patients, further driving market growth.

Challenges and Opportunities

What Are the Challenges Facing the IVIG Market?

Despite the promising prospects, the IVIG market faces several challenges. High equipment costs, a shortage of skilled professionals, and regulatory hurdles are some of the key issues impeding market growth. The complex nature of the technology necessitates continuous employee training, which can be costly and time-consuming.

How Is the Market Overcoming These Challenges?

The market is gradually overcoming these challenges through continuous innovation and strategic initiatives. For instance, manufacturers are focusing on reducing the costs of IVIG systems and improving their user-friendliness. Additionally, partnerships between manufacturers and research institutions are helping to address the shortage of skilled professionals by providing training and support.

Expanding Applications of IVIG Therapy

How Are Expanding Applications in Research and Development Boosting Demand?

The expanding applications of IVIG therapy in research and development activities are expected to boost product demand during the forecast period. For example, IVIG is being used in the treatment of autoimmune diseases, neurological disorders, and primary immunodeficiency diseases. The growing burden of these conditions globally is driving the demand for IVIG therapy, as it helps bolster the immune response and provides protection against infections.

What Are the Key Areas of Focus for Research and Development?

Research and development activities are focused on enhancing the safety and efficacy profiles of IVIG products. Manufacturers are investing in innovations such as plasma fractionation technologies, purification processes, and viral inactivation techniques to produce high-quality IVIG products. Additionally, efforts are being made to develop novel IVIG formulations that offer convenience in storage and administration.